Business
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a c...
About this update from Bolt Metals Corp.
[{"type":"text","content":"Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025\n\n\n\n REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will present data from the Phase 1 dose-escalation clinical study of BDC-3042 in patients with advanced cancers at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.\n \n\n BDC-3042 is a proprietary agonist antibody that targets dectin-2, an immune-activating receptor expressed by tumor-associated macrophages (TAMs). This single-agent, dose-escalation Phase 1 clinical study is evaluating BDC-3042 in patients with metastatic or unresectable solid tumors including non-small cell lung cancer (NSCLC).\n \n\n Bolt will also be presenting preclinical data from two of its pipeline programs, Boltbody™ ISACs targeting CEA and PD-L1.\n \n\n Details about the poster presentations can be found below and on the AACR website. Additionally, a copy of each poster will be available on the\n \n\n Publications\n \n\n page of the Bolt Biotherapeutics website at the start of each poster session.\n \n\n\n Title:\n \n BDC-3042, a first-in-class Dectin-2 agonist, in patients with advanced malignancies: Results from the first-in-human dose-escalation study\n \n\n Presenter:\n \n Ecaterina E. Dumbrava, M.D., The University of Texas MD Anderson Cancer Center\n \n\n Poster Session:\n \n First-in-Human Phase I Clinical Trials 2\n \n\n Session Date and Time:\n \n Tuesday, April 29, 2025, 9:00 a.m. – 12:00 p.m. CDT\n \n\n Location:\n \n Poster Section 48\n \n\n Poster Number:\n \n 20\n \n\n Abstract Number:\n \n CT154\n \n\n\n Title:\n \n A highly efficacious next-generation CEACAM5 (CEA)-targeted Boltbody™ ISAC for the treatment of colorectal, pancreatic and lung tumors\n \n\n Presenter:\n \n Paul D. Ponath, Ph.D., Bolt Biotherapeutics\n \n\n Poster Session:\n \n T Cell Engagers and Novel Antibody-Based Therapies\n \n\n Session Date and Time:\n \n Wednesday, April 30, 2025, 9:00 a.m. – 12:00 p.m. CDT\n \n\n Location:\n \n Poster Section 40\n \n\n Poster Number:\n \n 25\n \n\n Abstract Number:\n \n 7399\n \n\n\n Title:\n ...